DAFNA Capital Management LLC Sells 19,648 Shares of BioLineRx Ltd. (BLRX)
DAFNA Capital Management LLC decreased its holdings in BioLineRx Ltd. (NASDAQ:BLRX) by 2.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 980,352 shares of the biotechnology company’s stock after selling 19,648 shares during the quarter. DAFNA Capital Management LLC owned 1.03% of BioLineRx worth $828,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Sabby Management LLC purchased a new position in shares of BioLineRx in the first quarter valued at approximately $3,018,000. KCG Holdings Inc. boosted its stake in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 153,687 shares during the period. Renaissance Technologies LLC purchased a new position in shares of BioLineRx in the first quarter valued at approximately $126,000. Finally, Citadel Advisors LLC boosted its stake in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 86,481 shares during the period. 32.27% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “DAFNA Capital Management LLC Sells 19,648 Shares of BioLineRx Ltd. (BLRX)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/dafna-capital-management-llc-sells-19648-shares-of-biolinerx-ltd-blrx.html.
Several research firms have recently commented on BLRX. Zacks Investment Research raised shares of BioLineRx from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Tuesday. HC Wainwright set a $4.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. Roth Capital set a $3.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. BioLineRx currently has an average rating of “Buy” and a consensus target price of $2.88.
BioLineRx Ltd. (NASDAQ BLRX) traded down 1.9234% on Friday, hitting $1.2799. 338,498 shares of the stock traded hands. The stock’s market cap is $122.38 million. The firm’s 50-day moving average price is $1.09 and its 200-day moving average price is $0.97. BioLineRx Ltd. has a 12-month low of $0.80 and a 12-month high of $1.42.
BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.05). On average, equities research analysts anticipate that BioLineRx Ltd. will post ($0.24) EPS for the current fiscal year.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.